28-Mar-2024
No headlines found.
Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO (selinexor)
Business Wire (Wed, 13-Mar 4:35 PM ET)
PRNewswire (Wed, 6-Mar 4:05 PM ET)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Fri, 1-Mar 4:05 PM ET)
PRNewswire (Thu, 29-Feb 7:30 AM ET)
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
PRNewswire (Thu, 22-Feb 7:00 AM ET)
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
PRNewswire (Mon, 8-Jan 8:30 AM ET)
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
PRNewswire (Wed, 3-Jan 7:00 AM ET)
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Karyopharm Therapeutics trades on the NASDAQ stock market under the symbol KPTI.
As of March 28, 2024, KPTI stock price climbed to $1.51 with 1,251,126 million shares trading.
KPTI has a beta of 1.77, meaning it tends to be more sensitive to market movements. KPTI has a correlation of 0.07 to the broad based SPY ETF.
KPTI has a market cap of $171.15 million. This is considered a Micro Cap stock.
Last quarter Karyopharm Therapeutics reported $34 million in Revenue and -$.36 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.05.
In the last 3 years, KPTI stock traded as high as $14.73 and as low as $.62.
The top ETF exchange traded funds that KPTI belongs to (by Net Assets): IWM, VTI, VXF, IWO, VTWO.
KPTI stock has underperformed the market in the last year with a return of -56.7%, while SPY returned +33.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in KPTI shares. However, KPTI has outperformed the market in the last 3 month and 2 week periods, returning +63.5% and +6.3%, while SPY returned +10.1% and +1.7%, respectively. This indicates KPTI has been having a stronger performance recently.
KPTI support price is $1.39 and resistance is $1.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KPTI stock will trade within this expected range on the day.